Weight-Loss Jab Searches Grew 37x. The Diet Industry Halved.

A note on what this is before we start. This post is about search demand and what it did to a market. It is not medical advice, it takes no view on whether anyone should take these medicines, and the clinical questions belong with a doctor rather than a marketing agency.

With that said: this is the biggest thing that has happened in UK search in the four years I have been looking at this data, and it is not close.

Mounjaro, Wegovy, Ozempic and "weight loss injections" together went from about 30,000 UK searches a month in the year to June 2022 to more than 1.1 million in the year to April 2026. That is a 37-fold increase, and it now runs at more than ten times the size of the entire padel boom I wrote about a fortnight ago.

Mounjaro on its own went from 170 searches a month to 673,000.

Nothing was added. Something was replaced.

The instinct with a number that big is to assume a new market appeared. It mostly did not.

Slimming World, Weight Watchers and keto searches combined have gone from 441,500 a month to 228,600 over exactly the same period. Down 48%. The two lines crossed in 2024 and have gone in opposite directions ever since.

Slimming World alone has fallen from 246,000 to 135,000. Weight Watchers, a brand with more than sixty years of history, is down to 33,100 searches a month in the UK.

That is not a category expanding. That is one answer to a problem being substituted for another, at speed, and it is the single clearest example of search-led disruption I have in any of these posts. If you had been running a weight-management business on brand equity built over decades, four years of this would have taken roughly half your demand away regardless of what you did.

Being the famous one is not the same as winning

Ozempic was the name that made this category famous. It peaked in the year to June 2025 at 301,000 searches a month and has since fallen 45%.

Mounjaro passed it and kept going. Part of that is licensing, these medicines are approved for different things, and Mounjaro carries the weight-management licence in the UK. But the marketing lesson stands on its own: Ozempic did the work of teaching an entire country that this category existed, and then watched a competitor collect most of the demand it had created.

Where that demand actually goes

NHS prescribing has grown enormously in absolute terms, from under 3,000 GP prescriptions a month in England in March 2024 to over 200,000 by May 2025.

It is still nowhere near the size of the search demand. NHS access runs through specialist weight-management services against defined clinical criteria, and fewer than half of integrated care boards have rolled out GP-led prescribing. The 2024 manufacturing shortage on higher doses has been resolved, so the binding constraint now is not supply of the drug. It is eligibility, rollout, and for the private route, price.

That makes this a different shape from the others in this series. Padel could build courts. Matcha has to grow more tea. Hyrox has run out of weekends. Here the product exists in sufficient quantity and the constraint is who is allowed to have it and who can afford it, which is a rationing problem rather than a scarcity one.

The commercial read

Here is the thing most people get wrong about this category. It looks like a million-search purchase intent goldmine. It is not.

"Mounjaro side effects" does 135,000 searches a month. "Buy mounjaro" does 8,100. The ratio is about sixteen to one. The overwhelming majority of this vast category is people trying to understand a medicine, its effects, its cost and whether it applies to them, and only a sliver of it is transactional.

Yet the clicks are priced as though everyone is buying: £10.19 on "mounjaro uk", £12.80 on "buy mounjaro", £9.38 even on the side-effects term. If you are bidding on this category on the assumption that volume equals intent, you are paying purchase-intent prices for an audience that is overwhelmingly still reading.

The genuine opportunity in a market like this is the informational layer, and it comes with an obligation. This is health information about a prescription medicine. Content that is careless here does real harm, and both the regulators and the search engines treat medical content with a scrutiny they do not apply to padel courts. If you cannot resource it properly, with clinical review and honest sourcing, the right decision is not to compete for it.

The wider point

Five sectors in, this is the one I would point at if someone asked why search data is worth watching at all.

A category that barely registered in 2022 is now over a million searches a month, and it took roughly half the demand from an industry that had looked permanent for decades. None of that showed up first in anyone's quarterly results. It showed up in what people typed into Google, about eighteen months before it showed up anywhere else.

You do not have to have a view on the medicine to take the commercial lesson, which is simply this: the thing that replaces your category will not look like a competitor, and you will see it in search demand long before you see it in your revenue.

We will keep pulling these apart sector by sector. If you want to know what the search data says about yours, come and ask us.

Sources

• UK search volume, cost per click and keyword difficulty: Semrush UK database, pulled 18 August 2026. Figures are 12-month averages, so this summer is not included.
• England GP prescribing volumes, NHS eligibility criteria and integrated care board rollout: reported NHS and NICE figures, 2025 to 2026.
• This post is search and market analysis only. It is not medical advice, and nothing in it should be used to make a decision about treatment.